News | December 31, 2023
Roche to buy LumiraDx’s technology platform for US$ 295 million
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
US FDA approval based on NEURO-TTRansform Phase III results
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Leading USA based genetic testing brand officially enters the Indian market
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Demonstrate significant bleed reduction in hemophilia A and B
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Subscribe To Our Newsletter & Stay Updated
